Alpha-GPC vs Chonluten
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Alpha-GPC is the most bioavailable form of choline, readily crossing the blood-brain barrier to rapidly increase acetylcholine levels. It enhances cognitive performance, supports GH secretion, and is used as an essential complement to many nootropic peptides (especially those that increase acetylcholine demand like Noopept and Dihexa).
- Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
- Half-Life
- ~4–6 hours
- Short (minutes for the peptide); sustained gene-regulatory effects
- Admin Route
- Oral, SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 300–600 mg
- 10 mg per day
- Frequency
- 1–2x daily
- Daily for 10–30 days
- Key Benefits
- Rapidly raises brain acetylcholine levels
- Enhances memory formation and recall
- Prevents headaches from nootropic peptides (choline donor)
- Stimulates growth hormone secretion (modest)
- Improves attention and processing speed
- Neuroprotective in Alzheimer's and cognitive decline
- Approved in Europe for Alzheimer's therapy
- Enhances power output in athletes (pre-workout)
- Supports bronchial mucosal regeneration and repair
- May improve mucociliary clearance in chronic respiratory conditions
- Anti-inflammatory effects on bronchial epithelium
- Pulmonary anti-aging and tissue preservation
- Supports lung function in COPD and chronic bronchitis
- Well tolerated in combination with other Khavinson bioregulators
- Short tripeptide with efficient cellular penetration
- Side Effects
- Headache (paradoxically, from excess acetylcholine at very high doses)
- Nausea at doses > 1200 mg
- Dizziness
- Fatigue at high doses
- +1 more
- Generally well tolerated
- Mild injection site reactions possible
- No significant adverse pulmonary events reported
- Stacks With
- —
- —